The combination of atezolizumab, an inhibitor of programmed death-ligand 1 (PD-L1), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, shows therapeutic promise for hepatocellular carcinoma (HCC) [1]. Here, CD274 is linked to hepatocellular carcinoma.